In a randomized controlled trial, neurokinin 3 receptor antagonist (NK3Ra) administration in women with PCOS decreased the frequency of LH pulses (indicative of pulsatile GnRH release) and also LH and testosterone concentrations (George et al., 2016). The gene discussed is PLOD1; the disease is polycystic ovary syndrome.